JP Morgan Maintains Overweight on Arrowhead Pharma, Raises Price Target to $95

Benzinga · 1d ago
JP Morgan analyst Brian Cheng maintains Arrowhead Pharma (NASDAQ:ARWR) with a Overweight and raises the price target from $88 to $95.